This inventor holds 1 USPTO granted patent. Top assignee: Bayer Healthcare Aktiengesellschaft. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: The Innovative Contributions of Drew N. Kelner
Introduction
Drew N. Kelner is a notable inventor based in Newbury Park, California. He has made significant contributions to the field of biochemistry, particularly in the development of peptides that have therapeutic applications for metabolic diseases.
Latest Patents
Drew N. Kelner holds a patent for a novel invention titled "Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptide." This invention provides innovative peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides have been shown to lower blood glucose levels more effectively than controls during glucose challenges. The polypeptides are stable in formulation and possess long half-lives. This invention offers a new therapy for patients with decreased endogenous insulin secretion, particularly for those suffering from type 2 diabetes. The invention includes a polypeptide selected from a specific group of VPAC2-related polypeptides or their functional equivalents. Additionally, it outlines methods for treating metabolic diseases in mammals by administering a therapeutically effective amount of the insulin secretagogue peptides. The patent also discloses methods for producing these peptides, both through recombinant and synthetic means. Drew N. Kelner has 1 patent to his name.
Career Highlights
Drew N. Kelner is associated with Bayer Healthcare Aktiengesellschaft, where he has contributed to various research initiatives. His work focuses on the development of innovative therapeutic solutions that address critical health issues.
Collaborations
Drew has collaborated with notable colleagues, including Yu-chang John Wang and Clark Qun Pan, to advance research in his field.
Conclusion
Drew N. Kelner's innovative work in peptide development represents a significant advancement in the treatment of metabolic diseases. His contributions continue to impact the field of biochemistry and offer hope for improved therapies for patients with insulin-related conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile